PAQ Therapeutics

About PAQ Therapeutics

PAQ Therapeutics is focused on developing innovative treatments for KRAS-driven cancers, which are prevalent in about 25% of tumors and key drivers in lung, colorectal, and pancreatic cancers. Utilizing targeted protein degradation (TPD), PAQ aims to degrade KRAS rather than inhibit it, potentially offering more effective and durable treatments with fewer side effects for cancers with limited treatment options.

Products & Services

KRAS Degraders:Best- and first-in-class therapeutic solutions targeting KRAS mutations in deadly cancers using targeted protein degradation (TPD) technology.

Specialties

KRAS Degradation Targeted Protein Degradation (TPD) Cancer Therapeutics KRAS Biology Medicinal Chemistry

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 39000000 MR: - FA: $39 million FAN: 39000000	D: 2025-05-07 FD: 2025-05-07	6 investors

Series B Latest

2025-05-07

$39.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

N

Nan Ji

Cofounder, President and Chief Executive Officer

A

Andrew Krivoshik

Chief Medical Officer

H

Huaixiang Hao

Cofounder and Head of Research

J

Joseph Donahue

Head of Clinical Operations

L

Lokesh Gakhar

Head of Program Management and Protein Sciences

E

Eric Rubin

Chair of Clinical Advisory Board

View 5 more team members with Pro

Unlock Full Team Directory

Recent News